🔗 Share this article

This year's Nobel Prize in medical science has been granted for transformative discoveries that illuminate how the immune system targets harmful infections while protecting the body's own cells.

Three esteemed researchers—from Japan Shimon Sakaguchi and American scientists Mary Brunkow and Dr. Ramsdell—received this honor.

Their research uncovered specialized "sentinels" within the immune system that eliminate rogue immune cells capable of attacking the organism.

The discoveries are now enabling innovative therapies for immune disorders and malignancies.

These laureates will share a monetary award worth 11m Swedish kronor.

Decisive Findings

"Their work has been essential for comprehending how the body's defenses functions and why we don't all suffer from severe self-attack conditions," stated the head of the award panel.

This team's research address a core mystery: In what way does the immune system protect us from numerous infections while leaving our healthy cells unharmed?

The body's protection system uses white blood cells that scan for indicators of infection, even pathogens and germs it has not met before.

These defenders employ sensors—known as recognition units—that are produced by chance in a vast number of variations.

That provides the defense network the capacity to combat a broad range of threats, but the randomness of the mechanism unavoidably creates immune cells that can attack the host.

Protectors of the Immune System

Researchers earlier knew that some of these problematic white blood cells were destroyed in the immune organ—where immune cells develop.

The latest Nobel Prize recognizes the discovery of T-reg cells—known as the immune system's "security guards"—which travel through the body to neutralize other immune cells that attack the healthy cells.

It is known that this mechanism malfunctions in self-attack conditions such as type-1 diabetes, multiple sclerosis, and rheumatoid arthritis.

A prize committee added, "These findings have laid the foundation for a novel area of investigation and accelerated the creation of innovative therapies, for example for tumors and immune disorders."

In malignancies, regulatory T-cells prevent the body from fighting the tumor, so studies are focused on reducing their quantity.

For autoimmune diseases, trials are testing boosting T-reg cells so the body is no longer being harmed. A similar approach could also be effective in minimizing the chances of organ transplant rejection.

Pioneering Studies

Prof Sakaguchi, from a Japanese institution, conducted tests on mice that had their thymus removed, leading to autoimmune disease.

He showed that injecting immune cells from healthy mice could prevent the disease—suggesting there was a mechanism for blocking immune cells from harming the body.

Mary Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Dr. Ramsdell, now at a biotech firm in a California city, were investigating an genetic autoimmune disease in mice and humans that resulted in the identification of a gene vital for the way T-regs function.

"The pioneering work has uncovered how the immune system is kept in check by T-reg cells, preventing it from mistakenly targeting the healthy cells," commented a leading physiology specialist.

"The work is a remarkable illustration of how fundamental biological study can have far-reaching consequences for public health."